Mucinous Cystic Neoplasm of Pancreas in a Pregnant Woman Presenting with Severe Anemia and Gastric Bleeding: Case Report and Review of the Literature. Farahmandi S, Elessawy M, Bauerschlag DO, Pecks U, Abdullazade S, Beckmann JH, Heilmann T, Rumpf AL, Maass N, Jansen P, Winkler V. Healthcare (Basel). 2021 May 6;9(5):540. doi: 10.3390/healthcare9050540.
Heilmann T, Maass N. Nachsorge nach Mammakarzinomerkran-kung. Gynäkologe 54, 77–82 (2021).
A Giant Mammary Hamartoma in a Young Breast Cancer Patient. Rumpf AL, Mathiak M, Schäfer FK, Caliebe A, Farrokh A, Elessawy M, Bauerschlag DO, Maass N, van Mackelenbergh M, Heilmann T. Breast Care (Basel). 2021 Feb;16(1):85-88. doi: 10.1159/000507604.
Evaluation of Laparoscopy Virtual Reality Training on the Improvement of Trainees' Surgical Skills. Elessawy M, Mabrouk M, Heilmann T, Weigel M, Zidan M, Abu-Sheasha G, Farrokh A, Bauerschlag D, Maass N, Ibrahim M, Kamel D. Medicina (Kaunas). 2021 Feb 2;57(2):130. doi: 10.3390/medicina57020130.
Cytoplasmic levels of high mobility group A2 determine survival prognoses in breast cancer patients. Heilmann T, Vondung F, Borzikowsky C, Krüger S, Elessawy M, Alkatout I, Wenners A, Bauer M, Klapper W, Röcken C, Maass N, Schem C, Trauzold A. Int J Biol Markers. 2020 Jun;35(2):20-28. doi: 10.1177/1724600820917990.
Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model. Heilmann T, Rumpf AL, Roscher M, Tietgen M, Will O, Gerle M, Damm T, Borzikowsky C, Maass N, Glüer CC, Tiwari S, Trauzold A, Schem C. Arch Gynecol Obstet. 2020 Jun;301(6):1493-1502. doi: 10.1007/s00404-020-05496-4.
Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. Heilmann T, Vondung F, Borzikowsky C, Szymczak S, Krüger S, Alkatout I, Wenners A, Bauer M, Klapper W, Röcken C, Maass N, von Karstedt S, Schem C, Trauzold A. J Mol Med (Berl). 2019 Aug;97(8):1155-1167. doi: 10.1007/s00109-019-01805-w.
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years. Heilmann T, Pfisterer J, Hempel AM, Saß S, Hedderich J, Pujade-Lauraine E, Harter P, du Bois A, Hilpert F. Gynecol Oncol. 2019 Jun;153(3):616-624. doi: 10.1016/j.ygyno.2019.02.015.
Accuracy of tumor size measurement: comparison of B-mode ultrasound, strain elastography, and 2D and 3D shear wave elastography with histopathological lesion size. Farrokh A, Maass N, Treu L, Heilmann T, Schäfer FK. Acta Radiol. 2019 Apr;60(4):451-458. doi: 10.1177/0284185118787354.
Physical Exercise During Pregnancy - How Active Are Pregnant Women in Germany and How Well Informed? Schmidt T, Heilmann T, Savelsberg L, Maass N, Weisser B, Eckmann-Scholz C. Geburtshilfe Frauenheilkd. 2017 May;77(5):508-515. doi: 10.1055/s-0043-107785.
Validation of psychomotor tasks by Simbionix LAP Mentor simulator and identifying the target group. Elessawy M, Wewer A, Guenther V, Heilmann T, Eckmann-Scholz C, Schem C, Maass N, Noe KG, Mettler L, Alkatout I. Minim Invasive Ther Allied Technol. 2017 Oct;26(5):262-268. doi: 10.1080/13645706.2017.1303516.
Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases. Schem C, Tower RJ, Kneissl P, Rambow AC, Campbell GM, Desel C, Damm T, Heilmann T, Fuchs S, Zuhayra M, Trauzold A, Glüer CC, Schott S, Tiwari S. J Bone Miner Res. 2017 Mar;32(3):536-548. doi: 10.1002/jbmr.3012.
Schem C, Maass N, Elessawy M, van Mackelenbergh MT, Heilmann T (2017) New substances in breast cancer treatment: Which options suit which patients? Der Gynäkologe 50:1-7.
Heilmann T, Dittmann L, van Mackelenbergh M, Mundhenke C, Weimer J, Arnold N, Maass N, Schem C. Arch Gynecol Obstet. 2016 Oct;294(4):813-23. doi: 10.1007/s00404-016-4104-z.
Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey. van Mackelenbergh MT, Lindner CM, Heilmann T, Alkatout I, Elessawy M, Mundhenke C, Maass N, Schem C. Geburtshilfe Frauenheilkd. 2016 Jan;76(1):46-52. doi: 10.1055/s-0041-110805.
TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model. Fritsche H, Heilmann T, Tower RJ, Hauser C, von Au A, El-Sheikh D, Campbell GM, Alp G, Schewe D, Hübner S, Tiwari S, Kownatzki D, Boretius S, Adam D, Jonat W, Becker T, Glüer CC, Zöller M, Kalthoff H, Schem C, Trauzold A.Oncotarget. 2015 Apr 20;6(11):9502-16. doi: 10.18632/oncotarget.3321.
Intra-operative use of one-step nucleic acid amplification (OSNA) for detection of the tumor load of sentinel lymph nodes in breast cancer patients. Heilmann T, Mathiak M, Hofmann J, Mundhenke C, van Mackelenbergh M, Alkatout I, Wenners A, Eckmann-Scholz C, Schem C. J Cancer Res Clin Oncol. 2013 Oct;139(10):1649-55. doi: 10.1007/s00432-013-1481-6.
Schem C, Wenners A, van Mackelenbergh MT, Heilmann T, Mathiak M, Jonat W, Mundhenke C (2013) Prädiktion beim Mammakarzinom. Der Gynäkologe 46:377-381.
Heilmann T, Wenners A, Mundhenke C (2012) Molecular profiling: Commentary. Gynäkologische Praxis 36:682-684.
Wenners A, Heilmann T, Mundhenke C (2012) Eribulin (Halaven) in advanced mammary carcinoma. Gynäkologische Praxis 36:741-743.
Diagnosis and management of an unilateral giant fibroadenoma of the breast in pregnancy. Heilmann T, Leuschner I, Hilpert F, Kümper C, Strauss A, Mundhenke C, Jonat W, Bauer M. Arch Gynecol Obstet. 2012 Jan;285(1):235-7. doi: 10.1007/s00404-011-1923-9.
Elessawy M, Mabrouk M, Heilmann T, Weigel M, Zidan M, Abu-Sheasha G, Farrokh A, Bauerschlag D, Maass N, Ibrahim M, Kamel D. Evaluation of Laparoscopy Virtual Reality Training on the Improvement of Trainees' Surgical Skills. Medicina (Kaunas). 2021 Feb 2;57(2):130. doi: 10.3390/medicina57020130. PMID: 33540817; PMCID: PMC7913105.
Elessawy, M., Schneekloth, S., Günther, V., Maass, N., Mettler, L., & Alkatout, I. (2020). Postoperative Telephone-Based Questionnaire on Quality of Life after Robotic-Assisted Laparoscopic Hysterectomy versus Conventional Total Laparoscopic Hysterectomy. Journal of clinical medicine, 9(9), 2849. https://doi.org/10.3390/jcm9092849
Pecks, U., Bornemann, V., Klein, A., Segger, L., Maass, N., Alkatout, I., Eckmann-Scholz, C., Elessawy, M., & Lütjohann, D. (2019). Estimating fetal cholesterol synthesis rates by cord blood analysis in intrauterine growth restriction and normally grown fetuses. Lipids in health and disease, 18(1), 185. https://doi.org/10.1186/s12944-019-1117-1
Günther V, Alkatout I, Elessawy M, Ackermann J, Maass N, Voigt M. Demographic influence on maternal weight gain during pregnancy: where will we end up? Arch Gynecol Obstet. 2018 Oct;298(4):717-723. doi: 10.1007/s00404-018-4865-7. Epub 2018 Aug 3. PMID: 30076545.
Elessawy M, Harders C, Kleinwechter H, Demandt N, Sheasha GA, Maass N, Pecks U, Eckmann-Scholz C. Measurement and evaluation of fetal fat layer in the prediction of fetal macrosomia in pregnancies complicated by gestational diabetes. Arch Gynecol Obstet. 2017 Sep;296(3):445-453. doi: 10.1007/s00404-017-4433-6. Epub 2017 Jun 19. PMID: 28631075.
Günther, V., Alkatout, I., Fuhs, C., Salmassi, A., Mettler, L., Hedderich, J., Maass, N., Elessawy, M., Schmutzler, A. G., & Eckmann-Scholz, C. (2016). The Role of Interleukin-18 in Serum and Follicular Fluid during In Vitro Fertilization and Intracytoplasmic Sperm Injection. BioMed research international, 2016, 6379850. https://doi.org/10.1155/2016/6379850
Elessawy M, Skrzipczyk M, Eckmann-Scholz C, Maass N, Mettler L, Guenther V, van Mackelenbergh M, Bauerschlag DO, Alkatout I. Integration and Validation of Hysteroscopy Simulation in the Surgical Training Curriculum. J Surg Educ. 2017 Jan-Feb;74(1):84-90. doi: 10.1016/j.jsurg.2016.06.007. Epub 2016 Aug 23. PMID: 27567366.
Elessawy M, Schollmeyer T, Mettler L, Jonat W, Schem C, von Hehn U, Alkatout I. The incidence of complications by hysterectomy for benign disease in correlation to an assumed preoperative score. Arch Gynecol Obstet. 2015 Jul;292(1):127-33. doi: 10.1007/s00404-014-3594-9. Epub 2014 Dec 23. PMID: 25534160.
Schollmeyer T, Elessawy M, Chastamouratidhs B, Alkatout I, Meinhold-Heerlein I, Mettler L, Jonat W, Weigel MT. Hysterectomy trends over a 9-year period in an endoscopic teaching center. Int J Gynaecol Obstet. 2014 Jul;126(1):45-9. doi: 10.1016/j.ijgo.2013.12.017. Epub 2014 Apr 13. PMID: 24825496.
van Mackelenbergh, M. T., Lindner, C. M., Heilmann, T., Alkatout, I., Elessawy, M., Mundhenke, C., Maass, N., & Schem, C. (2016). Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey. Geburtshilfe und Frauenheilkunde, 76(1), 46–52. https://doi.org/10.1055/s-0041-110805
Originalarbeiten
Schem, R.J. Tower, P. Kneissl,A.C. Rambow, G.M. Campbell, C. Desel, T. Damm, T. Heilmann, S. Fuchs, M. Zuhayra, A. Trauzold, C.C. Glüer , S. Schott, S. Tiwari, „Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases”, J Bone Miner Res, Bd. 32, 2017. M. Campbell, RJ. Tower, T. Damm, P. Kneissl, A.C. Rambow, C. Schem, S. Tiwari, CC. Glüer, „Tracking the Progression of Osteolytic and Osteosclerotic Lesions in Mice Using Serial In Vivo μCT: Applications to the Assessment of Bisphosphonate Treatment Efficacy”, J Bone Miner Res, Bd. 33, 2018.
Schott, S. Tiwari, R. Tower, A.C. Rambow, P. Kneissl, O. Will, G. Trompke, A. Trauzold, F. Roesel, C. Sohn, W. Jonat, C.C. Glüer, C. Schem, „Antimetabolite-bisphosphonate duplex drug and cytostatic targeting of tumor in a murine breast cancer bone metastases model”, ASCO Annual Meeting 2014 (Abstract: 131721), J Clin Oncol, Bd. 32, 2014. Schem, R. Tower, P. Kneissl, A.C. Rambow, G. Campbell, T. Heilmann, W. Jonat, C.C. Glüer, C. Sohn, S. Schott, S. Tiwari, „Evaluation of the covalently linked antimetabolite 5-FdU with alendronate in a preclinical breast cancer bone metastases mouse model”, 60. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe 2014 (Poster: PO_Onko01_13), Geburtshilfe und Frauenheilkunde, Bd. 74, 2014. Schem, R.J. Tower, P. Kneissl, A.C. Rambow, G.M. Campbell, T. Heilmann, A. Trauzold, W. Jonat, C.C. Glüer, S. Schott, S. Tiwari, „Inhibition of osteolytic tumor growth by 5-FdU-alendronate, a bisphosphonate conjugate that maintains bone formation: Implications for treatment of osteolytic bone lesions”, San Antonio Breast Cancer Symposium 2014 (Abstract: 386/ P6-17-02), Cancer Res, Bd. 75, 2015. Denkert C, Untch M, Benz S, Schneeweiss A, Weber KE, Schmatloch S, Jackisch C, Sinn HP, Golovato J, Karn T, Marmé F, Link T, Budczies J, Nekljudova V, Schmitt WD, Stickeler E, Müller V, Jank P, Parulkar R, Heinmöller E, Sanborn JZ, Schem C, Sinn BV, Soon-Shiong P, van Mackelenbergh M, Fasching PA, Rabizadeh S, Loibl S. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy. Ann Oncol. 2021 Jan 5:S0923-7534(20)43224-7. doi: 10.1016/j.annonc.2020.12.016.
Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer. 2020 Nov;8(2):e001261. doi: 10.1136/jitc-2020-001261.
Rüger AM, Schneeweiss A, Seiler S, Tesch H, van Mackelenbergh M, Marmé F, Lübbe K, Sinn B, Karn T, Stickeler E, Müller V, Schem C, Denkert C, Fasching PA, Nekljudova V, Garfias-Macedo T, Hasenfuß G, Haverkamp W, Loibl S, von Haehling S. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial. J Am Heart Assoc. 2020 Dec;9(23):e018143. doi: 10.1161/JAHA.120.018143.
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. PLoS One. 2020 Aug 25;15(8):e0238021. doi: 10.1371/journal.pone.0238021.
Heil J, Pfob A, Sinn HP, Rauch G, Bach P, Thomas B, Schaefgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer JU, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Ditsch N, Rody A, Große R, van Mackelenbergh M, Reinisch M, Karsten M, Golatta M; RESPONDER Investigators. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03. Ann Surg. 2020 Jul 9. doi: 10.1097
Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, Higgs BW, Jank P, Sinn HP, Huober J, Becker C, Blohmer JU, Marmé F, Schmitt WD, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching PA, Jackisch C, Untch M, Schneeweiss A, Loibl S. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020 Sep;31(9):1216-1222. doi: 10.1016/j.annonc.2020.05.015.
Karn T, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching PA, Sinn BV, Schrader I, Budczies J, Marmé F, Müller V, Holtrich U, Gerber B, Schem C, Young B, Hanusch CA, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Loibl S. A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial. Clin Cancer Res. 2020 Jan 13. pii: clincanres.1954.2019.
Witzel I, Loibl S, Wirtz R, Fasching PA, Denkert C, Weber K, Lück HJ, Huober J, Karn T, van Mackelenbergh M, Marmé F, Schem C, Stickeler E, Untch M, Müller V. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer. 2019 Dec;121(12):1009-1015.
Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne CH, Solbach C, Ingold Heppner B, Steiger K, Müller V, Fasching P, Karn T, van Mackelenbergh M, Marmé F, Schmitt WD, Schem C, Stickeler E, Loibl S, Denkert C. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. Eur J Cancer. 2019 Jun;114:76-88. doi: 10.1016/j.ejca.2019.04.010. Epub 2019 May 7
Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clin Cancer Res. 2019 Jul 1;25(13):3986-3995. doi: 10.1158/1078-0432.CCR-18-3258. Epub 2019 Apr 12.
Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018 Oct 10;16(1):179. doi: 10.1186/s12916-018-1163-y.
Schmidt T, Rudolph I, Wozniak T, Ruetters D, Van Mackelenbergh MT, Huebner J. Effect of ballroom dancing on the well-being of cancer patients: Report of a pilot project. Mol Clin Oncol. 2018 Sep;9(3):342-346. doi: 10.3892/mco.2018.1663. Epub 2018 Jun 28.
Hedemann N, Rogmans C, Sebens S, Wesch D, Reichert M, Schmidt-Arras D, Oberg HH, Pecks U, van Mackelenbergh M, Weimer J, Arnold N, Maass N, Bauerschlag DO. ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Oncotarget. 2018 Mar 23;9(22):16043-16058.
Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018 Jan;19(1):40-50.
van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching PA, Blohmer JU, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber KE, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat. 2018 Jan;167(1):59-71
Schmidt T, van Mackelenbergh M, Wesch D, Mundhenke C. Physical activity influences the immune system of breast cancer patients. J Cancer Res Ther. 2017 Jul-Sep;13(3):392-398
Schmidt T, Schwarz M, Van Mackelenbergh M, Jonat W, Weisser B, Röcken C, Mundhenke C. Feasibility study to evaluate compliance of physical activity over a long time period and its influence on the total activity score, glucose metabolism and physical and psychological parameters following breast cancer. Mol Clin Oncol. 2017 Mar;6(3):397-402.
Schmidt T, Berner J, Jonat W, Weisser B, Röcken C, van Mackelenbergh M, Mundhenke C. Influence of arm crank ergometry on development of lymphedema in breast cancer patients after axillary dissection: A randomized controlled trail. J Rehabil Med. 2017 Jan 19;49(1):78-83.
Elessawy M, Skrzipczyk M, Eckmann-Scholz C, Maass N, Mettler L, Guenther V, van Mackelenbergh M, Bauerschlag DO, Alkatout I. Integration and Validation of Hysteroscopy Simulation in the Surgical Training Curriculum. J Surg Educ. 2017 Jan - Feb;74(1):84-90.
Heilmann T, Dittmann L, van Mackelenbergh M, Mundhenke C, Weimer J, Arnold N, Maass N, Schem C. Head-to-head comparison of the impact of Aurora A, Aurora B, Repp86, CDK1, CDK2 and Ki67 expression in two of the most relevant gynaecological tumor entities. Arch Gynecol Obstet. 2016 Oct;294(4):813-23.
van Mackelenbergh MT, Marotte M, Alkatout I, von Kaisenberg CS, Eckmann-Scholz C. Increasing maternal body mass index is associated with fetal defects. IJWHR 2016; 4: 164–170
van Mackelenbergh MT, Lindner CM, Heilmann T, Alkatout I, Elessawy M, Mundhenke C, Maass N, Schem C. Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey. Geburtshilfe Frauenheilkd. 2016 Jan;76(1):46-52.
Wenners A, Hartmann F, Jochens A, Roemer AM, Alkatout I, Klapper W, van Mackelenbergh M, Mundhenke C, Jonat W, Bauer M. Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer. Int J Clin Oncol. 2016 Jun;21(3):548-56.
Günther V, Bauer I, Hedderich J, Mettler L, Schubert M, van Mackelenbergh MT, Maass N, Alkatout I. Changes of salivary estrogen levels for detecting the fertile period. Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:38-42.
Schmidt T, Weisser B, Dürkop J, Jonat W, van Mackelenbergh M, Röcken C, Mundhenke C. Comparing Endurance and Resistance Training with Standard Care during Chemotherapy for Patients with Primary Breast Cancer. Anticancer Res. 2015 Oct;35(10):5623-9.
Wenners A, Berlin L, Alkatout I, van Mackelenbergh M, Jonat W, Mundhenke C. Clinical implications of first and multiple locoregional breast cancer recurrences. Arch Gynecol Obstet. 2015 Jul;292(1):165-73.
Maass N, Schem C, Bauerschlag DO, Tiemann K, Schaefer FW, Hanson S, Muth M, Baier M, Weigel MT, Wenners AS, Alkatout I, Bauer M, Jonat W, Mundhenke C. Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer. Oncology. 2014;87(5):300-10.
Weigel MT, Rath K, Alkatout I, Wenners AS, Schem C, Maass N, Jonat W, Mundhenke C. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment. Oncology. 2014;87(4):232-45.
Tiemann K, Weigel MT, Alkatout I, Wenners AS, Mundhenke H, Schäfer FW, Bauer M, Schem C, Maass N, Jonat W, Mundhenke C. Significance of syndecan-1 expression in ductal carcinoma in situ of the breast. Anticancer Res. 2014 Jul;34(7):3607-16.
Schollmeyer T, Elessawy M, Chastamouratidhs B, Alkatout I, Meinhold-Heerlein I, Mettler L, Jonat W, Weigel MT. Hysterectomy trends over a 9-year period in an endoscopic teaching center. Int J Gynaecol Obstet. 2014 Jul;126(1):45-9.
Heilmann T, Mathiak M, Hofmann J, Mundhenke C, van Mackelenbergh M, Alkatout I, Wenners A, Eckmann-Scholz C, Schem C. Intra-operative use of one-step nucleic acid amplification (OSNA) for detection of the tumor load of sentinel lymph nodes in breast cancer patients. J Cancer Res Clin Oncol. 2013 Oct;139(10):1649-55.
Weigel MT, Banerjee S, Arnedos M, Salter J, A'hern R, Dowsett M, Martin LA. Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann Oncol. 2013 Jan;24(1):126-33.
Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'hern R, Evans DB, Lane HA, Johnston SR, Dowsett M. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast Cancer Res. 2012 Oct 17;14(5):R132
Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M, Martin LA. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res. 2012 May 18;14(3):R78
Weigel MT, Krämer J, Schem C, Wenners A, Alkatout I, Jonat W, Maass N, Mundhenke C. Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2012 Jan;160(1):74-8.
Bauerschlag DO, Ammerpohl O, Bräutigam K, Schem C, Lin Q, Weigel MT, Hilpert F, Arnold N, Maass N, Meinhold-Heerlein I, Wagner W. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology. 2011;80(1-2):12-20.
Martin LA, Ghazoui Z, Weigel MT, Pancholi S, Dunbier A, Johnston S, Dowsett M. An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids. 2011 Jul;76(8):772-6.
Martin LA, Davies GL, Weigel MT, Betambeau N, Hills MJ, Salter J, Walsh G, A'Hern R, Dowsett M. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res Treat. 2010 Oct;123(3):829-36.
Bauerschlag DO, Schem C, Tiwari S, Egberts JH, Weigel MT, Kalthoff H, Jonat W, Maass N, Meinhold-Heerlein I. Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer Res. 2010 Sep;30(9):3355-60.
Weigel MT, Dahmke L, Schem C, Bauerschlag DO, Weber K, Niehoff P, Bauer M, Strauss A, Jonat W, Maass N, Mundhenke C. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer. 2010 Aug 9;10:412.
Bauerschlag DO, Habermann M, Weimer J, Meinhold-Heerlein I, Hilpert F, Weigel M, Bauer M, Mundhenke C, Jonat W, Maass N, Schem C. Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer. Anticancer Res. 2010 Jul;30(7):2739-44.
Bauerschlag DO, Schem C, Weigel MT, Von Kaisenberg C, Strauss A, Bauknecht T, Maass N, Meinhold-Heerlein I. The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. J Cancer Res Clin Oncol. 2010 Jan;136(1):79-88.
Bräutigam K, Bauerschlag DO, Weigel MT, Biernath-Wüpping J, Bauknecht T, Arnold N, Maass N, Meinhold-Heerlein I. Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation. Transl Oncol. 2009 Aug 18;2(3):164-73.
Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling. Cancer Lett. 2009 Jan 8;273(1):70-9.
Mundhenke C*, Weigel MT*, Sturner KH, Roesel F, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Hilpert F, Jonat W, Maass N. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor mediated antiproliferative effects. J Cancer Res Clin Oncol. 2008 Dec;134(12):1397-405.
*contributed equally to this study
Dowsett M, Ghazoui Z, Martin LA, Mundhenke C, Weigel M. Treatment of endocrine resistant breast cancer. (2011) Patentnummern: EP2558098 A2, WO2011128434 A2
Van Mackelenbergh MT, Schem C. Diagnostik, Therapie und Nachsorge beim Mammakarzinom.
Der Gynäkologe Ausgabe 12/2016
Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C, Günther V. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health. 2015 Mar 20;7:305-13.
Van Mackelenbergh M, Maass N, Jonat W, Hilpert F. Ovarialkarzinom und Präkanzerosen. Der Gynäkologe Ausgabe 6/2015
Alkatout I, Order B, Klapper W, Weigel M, Jonat W, Schäfer FKW, Mundhenke C, Wenners A. Surgical impact of new treatments in breast cancer. Minverva Ginecol 2013; 65(5)
Schem C, Wenners AS, van Mackelenbergh MT, Heilmann T, Mathiak M, Jonat W, Mundhenke C. Prädiktion beim Mammakarzinom
Prädiktive molekulare Tests und Signaturen. Der Gynäkologe Ausgabe 6/2013
Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010 Sep 23;17(4):R245-62.
Summa B, Schem C, Weigel M, Strauss A, Jonat W, Maass N, Schäfer F, Bauerschlag DO. Leiomyomatosis peritonealis disseminata in a pregnant woman. Arch Gynecol Obstet. 2010 Jan;281(1):123-7.
Maass N, Weigel MT. Sectio cesarea (Kaiserschnitt) in Strauss A, Janni W, Maass N. Klinikmanual Gynäkologie und Geburtshilfe. Herausgeber: Springer Medizin Deutschland 2009
Clin Oncol, 2008 ASCO Annual Proceedings 26:14639.
Bauerschlag DO, Schem C, Tiwari S, Meinhold-Heerlein I, Mundhenke C, Weigel M, Egberts JH, Kalthoff H, Jonat W, Maass N. SU11248 (Sunitinib) does inhibit tumor growth and angiogenesis in ovarian cancer murine xenograft model. J Clin Oncol, 2008 ASCO Annual Proceedings 26:16557.
Mundhenke C, Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Jonat W, Maass N. Imatinib Mesylat zeigt in vitro einen deutlichen Effekt auf das Wachstum von. Ovarialkarzinomzellen. Archives of Gynecology and Obstetrics, Volume 276, Number 4, October 2007, pp. 395-462(68). Posterpräsentation bei der 20. Hochschullehrertagung in Lübeck 2007.
Mundhenke C, Weigel MT, Meinhold-Heerlein I, Schem C, Bauerschlag DO, Jonat W, Maass N. Imatinib mesylate inhibits the growth of breast cancer cells mediated by PDGF-receptor-β and Akt inactivation. J Clin Oncol, 2006 ASCO Annual Proceedings 24(18S):20040.
Mundhenke C, Weigel MT, Meinhold-Heerlein I, Schem C, Bauerschlag DO, Jonat W, Maass N. Effekte von Imatinib auf die Biologie von Mammakarzinomzellen in vitro. Geburtsh Frauenheilk, 2006 67(S1) S. 30. Posterpräsentation beim 56. Kongreß der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, Berlin.
Mundhenke C, Weigel MT, Meinhold-Heerlein I, Schem C, Bauerschlag DO, Jonat W. Effects of Imatinib on breast cancer cell biology in vitro. Vortrag beim 27. Deutschen Krebskongreß, Berlin.
Mundhenke C, Weigel MT, Meinhold-Heerlein I, Schem C, Bauerschlag DO, Jonat W, Maass N. Imatinib mesylate inhibits the growth of breast cancer cells mediated by PDGF-receptor-β and Akt inactivation. Breast Cancer Res Treat 2006; 100(Suppl 1): (Abstr 4118).
Mundhenke C, Weigel MT, Schmidt SR, Meinhold-Heerlein I, Schem C, Bauerschlag DO, Jonat W, Maass N. Effects of Imatinib on breast cancer cell biology in vitro. J Clin Oncol, 2005 ASCO Annual Proceedings 23(16S): 3210.
Maass N, Mundhenke C, Schmidt SR, Weigel MT, Meinhold-Heerlein I, Schem C, Bauerschlag DO, Hilpert F, Jonat W. Identification of potential molecular targets for Imatinib mesylate induced growth inhibition in breast cancer cell lines. J Clin Oncol, 2005 ASCO Annual Proceedings 23(16S): 3203.
Maass N, Mundhenke C, Weigel M, Jonat W. PDGF-beta und AKT vermittelte Wachstumshemmung von Mammakarzinomzellen durch Imatinib. Geburtsh Frauenheilk 2005; 66.